- Solid Tumors
- Pipeline Molecules
- Alliance Partners
Our mission is to provide healthcare professionals with unbiased clinical research information, easily.
Currently, you can access the following clinical trials being conducted worldwide:
CAR T cell therapy utilizes autologous T cells from a patient that have been modified with a chimeric antigen receptor (CAR).1 CARs are composed of an antigen-recognition domain, which is most often a single-chain variable fragment derived from a monoclonal antibody or an antigen-binding fragment, fused to signaling domains designed to redirect T cell function.1,2 CARs can allow the modified patient T cells to recognize tumor-cell antigens and initiate an immunologic response.1-3 Tumor cells are either targeted directly by CAR-modified T cells or through recruitment of other components of the immune system.1
See below for a depiction of the CAR T cell engineering process and description of identified targets (B-cell maturation antigen [BCMA] in multiple myeloma and CD19 in non-Hodgkin lymphoma).
Preclinical studies have demonstrated the activity of the CAR T cell approach.22,23 Various CAR T cell therapies are currently being investigated for the treatment of hematologic malignancies and solid tumors.
Celgene is developing CAR T cell therapies, including a collaboration with bluebird bio.